Overview

Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate dose-proportionality of Dilatrend SR 8mg, 16mg, 32mg, 64mg, 128mg in healthy male volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical
Collaborator:
Asan Medical Center
Treatments:
Carvedilol